Iovance Biotherapeutics (IOVA) Receives Conditional Approval for Amtagvi

Iovance Biotherapeutics, Inc. (IOVA) received conditional approval for Amtagvi from the Therapeutic Goods Administration of Australia on June 4, 2026. Following this, the stock surged from low levels reported on June 3, although it has since returned to pre-approval prices. The management forecasts Q2 revenue from Amtagvi to be between $79 million and $81 million. Despite a price target adjustment from $16 to $14 by Chardan, 80% of analysts remain bullish on IOVA, indicating ongoing investor interest.